Development of TCR Technology Platforms for Cancer Immunotherapy
- Highlight how next-generation of single chain TCR can prevent mispairing
- Share preclinical insights showing the potential of engineered stimulatory PD-L1 signalling for solid tumour applications
- Showcase the platform of targeted transduction for nonactivated T-cells